Why AdaptHealth Stock Plummeted This Week

AdaptHealth posted a huge earnings miss in Q2, and sales also came in below expectations.

The company also lowered its fiscal performance targets for the year.

AdaptHealth (NASDAQ: AHCO) stock got crushed this week after the company reported disappointing quarterly results. The company's share price ended the week's trading down 47% from where it stood at the end of the previous week's market close.

AdaptHealth reported its second-quarter results before the market opened on Aug. 4, with both sales and earnings for the period coming in below the market's expectations. With the big pullback this week, AdaptHealth stock is now down 38% over the last year.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

AdaptHealth's Q2 results came in far below Wall Street's targets. While the average analyst estimate had targeted a per-share profit of $0.15 in the quarter, the business actually wound up posting a loss of $1.07 per share in the period.

Sales increased roughly 12.7% year over year to reach $740.3 million, but the performance came in roughly $106.5 million lower than the average analyst forecast. Registered users on the company's myApp platform increased roughly 56% year over year to reach 512,000 but user growth for the service hardly excited investors in light of weak second-quarter numbers and downward guidance revisions.

With its Q2 report, AdaptHealth issued new forward guidance that disappointed investors. The company now expects sales to come in between $2.85 billion and $2.89 billion. The company had previously guided for sales to be between $3.45 billion and $3.52 billion for the year. Meanwhile, the average analyst estimate had called for sales of roughly $3.49 billion. The big downward revision was largely due to the discontinuation of its Diabetes Health business and shifting its guidance to only include continuing operations, but the forecast was disappointing nonetheless.